Stock reports › US › Healthcare
Eli Lilly and Company (LLY) stock analysis
Eli Lilly hits record territory after Q3 beat, with valuation and drug pricing risk in focus
Eli Lilly closed at 1,437.76 on Nov 11, 2026, 1.05% below its 52-week and all-time high of 1,453.00, after a 10.03% post-earnings move on Oct 29. Revenue growth of 45.51% year over year and a 46.07% operating margin sit alongside a forward P/E of 29.96, in the 82nd percentile of US Healthcare. The mean analyst target of 1,456.69 is only 1.32% above the price.
- Price: 1,415.55
- Market Cap (USD): $1.26T
- P/E: 45.78×
- Fwd P/E: 29.11×
- Div Yield: 0.49%
- 1Y Return: 38.06%
- Next Earnings: Feb 3, 2027
- Mean Target: 1,453.18
- Rating: Strong Buy
Bull case
- Revenue grew 45.51% year over year and 38.61% in the latest quarter, with six straight quarters of rising revenue; the 3-year revenue CAGR is 31.69%.
- The Oct 29, 2026 report beat EPS consensus by 31.00% (7.48 vs 5.71) and revenue by 8.03%, extending the EPS beat streak to 8 quarters.
- Returns are very high: ROIC of 37.07% (91st percentile of US Healthcare) and an operating margin of 46.07% against a sector median of 15.17%.
Bear case
- Forward P/E of 29.96 is well above the industry median of 15.82 and the sector median of 18.61, and the free cash flow yield is only 1.53%.
- The price is 1,437.76 versus a mean analyst target of 1,456.69, leaving only 1.32% upside; one downgrade was recorded in the last 30 days and next year's EPS estimates were revised down 0.88%.
- A Nov 11, 2026 Benzinga headline flags near-term drug pricing risk as Washington turns up pressure; insiders also sold, with a net value of -14.7M over 90 days and no buys.
What to watch
- Ex-dividend date Nov 13, 2026 (quarterly dividend of 1.73, payable Dec 10, 2026).
- The 52-week and all-time high of 1,453.00, and the 20-day average at 1,338.16 as nearby support.
- Next earnings on Feb 3, 2027 (not yet confirmed); consensus EPS is 11.19.
- Follow-through on the Nov 12, 2026 Reuters report that China approved the weight loss pill orforglipron.
General
Eli Lilly is a pharmaceutical company covering diabetes, oncology, immunology and neuroscience, and its numbers are growing fast. The stock trades near record highs at a premium valuation, and analysts' targets sit close to the price.
Business and momentum
Eli Lilly discovers, develops, manufactures and sells pharmaceuticals. Trailing revenue is $86.46B with net income of 27.58B. Revenue grew 45.51% year over year. In 2025 the US made up 66.71% of revenue and China 2.99%. The stock is up 48.74% over one year and 33.78% year to date.
Valuation in context
The trailing P/E is 46.50 and the forward P/E is 29.96, in the 82nd percentile of US Healthcare against a sector median of 18.61. The PEG ratio is 0.72, helped by next-year EPS growth of 41.53% that analysts expect. Price to sales is 14.83, in the 91st percentile.
Analyst and market signals
Analyst consensus on Nov 12, 2026 was 34 Buy, 9 Hold and 3 Sell. The mean target is 1,456.69, just above the price. Raymond James moved from Underperform to Market Perform on Oct 30, 2026. Short interest is low at 0.81% of float.
Main risks
Drug pricing pressure from Washington was highlighted by Benzinga on Nov 11, 2026. The stock has had large earnings swings, including -16.17% in Aug 2025, and a 1-year maximum drawdown of -23.31%. High expectations are embedded in the premium valuation.
Long-term investor
Growth, margins and returns on capital are far above sector medians, and the balance sheet is serviceable. The question for a multi-year owner is whether growth justifies a forward P/E of 29.96 and a thin free cash flow yield.
Growth durability
Annual revenue rose from 28.54B in 2022 to 65.18B in 2025, and EPS from 6.57 to 22.95. Quarterly revenue rose from 13.53B in Q4 FY2024 to 24.40B in Q3 FY2026. Quarterly EPS has been uneven, with 7.22 in Q3 FY2026 against 8.26 in Q1. Next year's EPS growth is estimated at 41.53%.
Margins and returns
Gross margin is 83.63% and operating margin 46.07%, up 1.65% from a year ago. ROIC is 37.07% (91st percentile) and ROE is 86.10%, which is boosted by a modest equity base of 40.27B. Free cash flow was 19.66B over the last twelve months, up 117.95%.
Balance sheet and capital return
Total debt is 49.50B against 4.88B in cash, giving net debt of 44.62B, or 1.00 times EBITDA. Interest coverage is 33.81. In 2025 the company repurchased 4.11B of stock and paid 5.38B in dividends. The yield is 0.47% with 11 years of dividend growth and a 21.71% payout ratio.
Valuation, revisions and holders
Forward P/E is in the 82nd percentile and EV/EBITDA 29.65 in the 84th. EPS estimates were revised down 0.88% over 30 days while revenue estimates rose 2.88%. Insiders had 2 sales and no buys in 90 days, and institutions own 88.92%, as of Jun 30, 2026.
Swing trader
The trend is strongly up, with price above all key averages, but momentum is stretched with RSI at 70.35. The stock sits 1.05% under its high, so a break or a pullback toward the averages are the key scenarios.
Trend and momentum
Price of 1,437.76 is 7.44% above the 20-day average (1,338.16), 16.88% above the 50-day (1,230.07) and 30.09% above the 200-day (1,105.21). RSI is 70.35, MACD 57.36 is above its signal of 51.85, and ADX of 38.08 shows a strong trend. The relative strength rating is 94.
Recent sessions and levels
The stock rose from 1,288.30 on Oct 28 to 1,373.70 on Oct 29 after earnings, then reached a high of 1,453.00 on Nov 5 before closing at 1,364.73 that day. It recovered to 1,437.76 by Nov 11 on 1.8M shares, below the 10-day average volume of 3.7M. The 20-day low is 1,230.66.
Volatility and risk
The 14-day average true range is 46.36, or 3.22% of price. Ten-day historical volatility of 45.72% is above the 90-day 31.89%. The 1-year beta is 0.33. Stochastic %K of 92.2 signals an extended short-term reading.
Calendar and flow
The ex-dividend date is Nov 13, 2026 (1.73). Next earnings are Feb 3, 2027, outside most near-term windows. Short interest was 7.2M shares (0.81% of float) on Oct 30, up 3.64%. Analysts mostly reiterated ratings after earnings, with several targets between 1,497 and 1,650.
Options
Implied volatility is low relative to its own 52-week range, and options trade at a discount to recent realized volatility. Liquidity is strong and the next earnings date falls outside a 30-day expiry.
Implied volatility level
30-day implied volatility is 31.55%, with a 52-week rank of 18 and percentile of 15, against a range of 27.81% to 48.04%. It fell 12.7 points over 20 days. The term structure is in contango, with 90-day implied volatility at 34.65%, and the 25-delta skew is +4.7 points.
Implied versus realized
The 30-day implied volatility of 31.55% compares with 30-day historical volatility of 34.90%, a ratio of 0.90. The volatility risk premium is -7.3 points, so premium is not rich relative to realized volatility; the 10-day realized figure is 45.72%.
Expected moves and earnings
The expected move is 4.37% over 7 days and 9.04% over 30 days. Earnings are not before the Dec 11, 2026 expiry. Past earnings moves averaged 8.33% over 8 quarters with a maximum of 16.17%, and average implied volatility crush was 7.37%.
Premium yields and liquidity
For the 30-day expiry, the cash-secured put near the 30-delta (1,385.00 strike, 3.67% out of the money) yields 28.18% annualized. The covered call near 1,520.00 yields 16.27% annualized and the ex-dividend date falls before expiry. The liquidity score is 93, and the put/call volume ratio is 1.62.
Analysis written November 12, 2026 from Qanvo data as of November 11, 2026. AI-generated, for information only; not investment advice.